We will have to be patient because progress 'hints' on the most important trial endpoints - i.e. clinical efficacy - are unlikely before mid year or later.
Nevertheless, news flow in the first 6 months is likely to include:
1. Progress with recruitment
2. Commencement of trials at PA and Melbourne Hospitals (unless all 30 Phase 1 recruits are scheduled for Liverpool)
3. Results of Phase 1 - device validation and safety confirmation (in accordance with TGA requirements) and algorithm enhancement
4. Updated timetable for Phase 2 - specificity and sensitivity
Great time for a top-up!
- Forums
- ASX - By Stock
- Ann: EMVision Commences Clinical Trial
We will have to be patient because progress 'hints' on the most...
Featured News
Add EMV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.02 |
Change
0.033(1.64%) |
Mkt cap ! $172.5M |
Open | High | Low | Value | Volume |
$1.98 | $2.02 | $1.94 | $41.93K | 21.40K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1272 | $1.96 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.03 | 4500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1272 | 1.960 |
1 | 2383 | 1.940 |
1 | 1000 | 1.930 |
3 | 12012 | 1.910 |
4 | 34592 | 1.900 |
Price($) | Vol. | No. |
---|---|---|
2.030 | 4500 | 1 |
2.050 | 7750 | 3 |
2.100 | 5862 | 1 |
2.130 | 2958 | 1 |
2.150 | 2826 | 1 |
Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
Featured News
EMV (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online